Telix Pharmaceuticals to Acquire ITM in ~$1.65B Radiopharma Deal

Shots: Telix has entered into a strategic agreement to lead a merger with ITM Isotope Technologies Munich, with Telix shareholders expected to own ~76.3% & ITM shareholders ~23.7% of Telix shares upon completion As per the deal, Telix will acquire 100% of ITM for $1.65B upfront, comprising $1.25B in the form of 105.8M Telix shares,…

ByRidhi RastogiSeptember 22, 2026

ITM Reports Topline Data from P-III (COMPETE) Trial of ITM-11 at the ENETS 2025 Conference

Shots: The P-III (COMPETE) trial assessed ITM-11 (n=207) vs everolimus (n=102) in pts (N=309) with inoperable, progressive, SSTR+ Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs). The US FDA’s NDA filing is expected in 2025 The study met its 1EP of improved PFS with mPFS of 23.9 vs 14.1mos., while dosimetry data, ORR, QoL…

ByRidhi RastogiMarch 6, 2025

ITM Reports Topline Data from P-III (COMPETE) Trial of ITM-11 to Treat Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Shots: The P-III (COMPETE) trial assessed ITM-11 (7.5 GBq + nephroprotective amino acid, Q3M × max. 4 cycles) vs everolimus (10mg for ~30mos. or until disease progression) in patients (n=309) with inoperable, progressive, SSTR+ gr 1/2 GEP-NETs. The US FDA’s NDA submission is expected in 2025 The study met its 1EP of improved PFS,…

BySenior EditorJanuary 29, 2025

Telix Pharmaceuticals to Acquire ITM in ~$1.65B Radiopharma Deal

ITM Reports Topline Data from P-III (COMPETE) Trial of ITM-11 at the ENETS 2025 Conference

ITM Reports Topline Data from P-III (COMPETE) Trial of ITM-11 to Treat Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Contact US

FOLLOW US